Novo Nordisk A/S – Reduction of the share capital

Bagsvaerd, DENMARK


Novo Nordisk A/S – Reduction of the share capital

Bagsværd, Denmark, 28 April 2020 – At Novo Nordisk’s Annual General Meeting on 26 March 2020, it was decided to reduce the company’s B share capital from DKK 372,512,800 to DKK 362,512,800 by cancellation of part of the company’s portfolio of own B shares equal to a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each.

Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares at a nominal value of DKK 10,000,000. After the reduction of the share capital, the company’s share capital is nominally DKK 470,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 362,512,800.

The reduction of the share capital will not affect Novo Nordisk’s share repurchase programme which will continue as previously announced.
                                      

Further information

Media:  
Anne Margrethe Hauge+45 4442 3450amhg@novonordisk.com
Ken Inchausti (US)+1 609 786 8316kiau@novonordisk.com
   
Investors:  
Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.com
Valdemar Borum Svarrer+45 3079 0301jvls@novonordisk.com
Ann Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.com
Mark Joseph Root+45 3079 4211mjhr@novonordisk.com
Kristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com


Company announcement No. 25 / 2020

Attachment


Attachments

CA20200428 - Novo Nordisk - Reduction of the share capital